Get the actual HTA-insights from Singapore. Here are the outcomes compiled by Vista Health.

 

🏛️ Out of 14 pharmaceutical submissions, only 4 drugs (29%) received a full listing.

 

❌ 10 out of 14 drugs (71%) were not listed which included:

🔹 6 oncology drugs (43%), such as treatments for NSCLC, lymphoma, leukaemia, and colorectal cancer.

🔹 4 non-oncology drugs (29%), spanning indications like migraine, chronic kidney disease, and osteoporosis.

 

📌 Common reasons for negative listing decisions included:

🔹 Unfavourable cost-effectiveness compared to existing subsidised treatments.

🔹 Unacceptable pricing or price-volume agreements (PVA) proposed by manufacturers.

🔹 Uncertain comparative clinical effectiveness or unclear magnitude of clinical benefit.

 

📝 Register here to receive the latest and upcoming issues of the complete Access Briefing with HTA insights from 14 countries, compiled by 9 partners of our network 👉 https://forms.office.com/e/Jt8bPmVkdJ